У нас вы можете посмотреть бесплатно CURIS (CRIS) SHOCK DATA: 83% Response! But CAN THEY SURVIVE Q4 2025? или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
CURIS (CRIS) SHOCK DATA 83% Response! But CAN THEY SURVIVE Q4 2025? 🔥 Curis (CRIS) is walking a tightrope! 🔥 We're diving DEEP into biotech company Curis, Inc. and their lead cancer therapeutic, emavusertib. This experimental drug is showing INCREDIBLY promising early data in tough-to-treat cancers like Primary Central Nervous System Lymphoma (PCNSL) and Acute Myeloid Leukemia (AML), with response rates that could be game-changing. But there's a HUGE catch. Curis is facing a critical cash crunch, with funds potentially running out by Q4 2025 – the exact time crucial data readouts are expected! Add to that significant shareholder dilution and a looming NASDAQ delisting notice, and the stakes couldn't be higher. In this episode, we unpack: ✅ The science behind emavusertib (IRAK4, FLT3, CLK inhibition) ✅ Jaw-dropping clinical trial data for PCNSL (up to 83% ORR!) and AML (outperforming comparators?) ✅ Curis's dire financial situation: burn rate, cash runway, and dilution. ✅ The impact of the new CMO, Dr. Ahmed Hamdy. ✅ Key catalysts and risks: NASDAQ compliance, Q4 2025 data, and the desperate need for funding or partnership. Is Curis on the verge of a massive breakthrough or a financial collapse? Join us as we analyze the opportunities, the immense risks, and what investors NEED to watch out for. #Curis #CRIS #Emavusertib #Biotech #Biotechnology #CancerResearch #Oncology #PCNSL #AML #MDS #ClinicalTrials #StockMarket #Investing #BiotechInvesting #SmallCapStocks #Pharma #HealthcareInvesting #DrugDevelopment #FinancialAnalysis #HighRiskHighReward Disclaimer: The content of this podcast is for informational purposes only and should not be considered financial or investment advice. Always conduct your own research and consult with a financial advisor before making any investment decisions.